A Global Real World Platform Study Evaluating Teclistamab or Talquetamab as Primary Treatment for Patients with Relapsed or Refractory Multiple Myeloma who are Triple class Exposed in the Prior Lines of Therapy

A Global Real World Platform Study Evaluating Teclistamab or Talquetamab as Primary Treatment for Patients with Relapsed or Refractory Multiple Myeloma who are Triple class Exposed in the Prior Lines of Therapy - CoMMitmenTT

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000061790

Enrollment

350

Registered

2026-06-03

Start date

2026-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with Relapsed or Refractory Multiple Myeloma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Has a confirmed diagnosis of RRMM 2. Treated with Teclistamab (Tec) or (Tal) (for Tec and Tal cohorts, respectively) after commercial launch date in each country 3. Received at least one full dose of cohort treatment (for the Tec and Tal cohorts, respectively), with the cohort treatment as monotherapy 4. Aged at least 18 years at initiation of Tec or Tal (for the Tec and Tal cohorts, respectively) 5. Had >= 1 month follow-up from the initiation of Tec or Tal (for the Tec and Tal cohorts, respectively). Patients will be eligible if they died within 1 month of Tec or Tal initiation (for the Tec and Tal cohorts, respectively). Patients are not required to be on Tec or Tal for >= 1 month (for the Tec and Tal cohorts, respectively). 6. Patients whose consent to participate in this study has been obtained from the patient or the legally acceptable representative (However, if the Independent Ethics Committee/Institutional Review Board approves, including cases in which it is difficult to obtain consent from the patient or the legally acceptable representative due to death or other reasons, opt-out enrollment will be permitted.)

Exclusion criteria

Exclusion criteria: 1.Received Tec or Tal treatment for MM as part of a clinical trial (for the Tec and Tal cohorts, respectively). 2.Received Tec or Tal treatment as bridging therapy for CAR-T (for the Tec and Tal cohorts, respectively) 3.Received Tec + Tal combination therapy

Design outcomes

Primary

Measure	Time frame
The patient characteristics, treatment patterns, and associated outcomes	—

Countries

Japan,South America,Europe

Contacts

Public ContactTatsunori Jinnai

Johnson & Johnson Innovative Medicine Janssen Pharmaceutical K.K. Medical affairs

tjinnai@its.jnj.com03-4411-7700

Outcome results